Mounjaro (Tirzepatide) 15mg

Mounjaro is a prescription-only treatment for weight loss and type 2 diabetes. It comes as a weekly self-injectable pen and contains the active ingredient tirzepatide. It works by suppressing appetite, making you feel less hungry.

Mounjaro mimics hormones that naturally occur in the gut after eating, called incretins. Incretins have many functions, such as:

• slowing down the emptying of the stomach
• sending signals to your brain that you’re full after eating
• increasing insulin levels

These combined effects help people feel full after a meal by signalling to the parts of the brain responsible for appetite, making it easier to eat less.

Who is eligible for Mounjaro?

To be eligible for Mounjaro, you must have:

• a BMI (body mass index) of 30 kg/m² or over (obese)
• a BMI between 27 and 30 kg/m² (overweight), and a weight-related health condition such as high cholesterol, high blood pressure, pre-diabetes or heart problems

You’ll also need to have no health problems or take any medications that may interact with taking Mounjaro,

Find out if you are eligible through our online assessment.

The active ingredient tirzepatide works by activating the receptors of 2 natural incretin hormones: GIP and GLP-1. Both of these hormones affect your appetite by slowing down the emptying of the stomach after a meal. They also send signals to your brain to reduce your appetite after eating. This action creates a feeling of being full and so makes you feel less hungry, even when you have eaten less, which can aid in weight loss.

For diabetic patients, Mounjaro increases the production of insulin, which is released into your body to lower blood sugar levels.

Mounjaro is an effective treatment for both weight loss and regulating blood sugar levels. A recent clinical trial has shown that people who used Mounjaro lost up to 22.5% of their body weight on the highest maintenance dose (15mg tirzepatide, once per week) within 72 weeks.

Here is a detailed breakdown of the average weight change for each maintenance dosage in comparison to participants who took the placebo from the same clinical trial: